Bear Stearns keeps Amgen at peer perform

Amgen Inc. was maintained at a peer perform rating by Bear Stearns analyst Mark Schoenebaum on news that Roche filed a motion to dismiss Amgen's lawsuit regarding CERA, claiming that CERA is not a marketed product and cannot infringe a patent. Separately, Amgen filed a complaint with the U.S. International Trade Commission alleging infringement. There is no new information on CERA's efficacy or composition released. Shares of the Thousand Oaks, Calif., biotechnology company were down $0.27, or 0.38%, at $69.97 on volume of 8,257,564 shares versus the three-month running average of 10,783,000 shares. (Nasdaq: AMGN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.